Comparing non-vertebral fracture risk reduction with osteoporosis therapies: looking beneath the surface
- 139 Downloads
Data from pivotal trials of pharmacologic agents used to treat osteoporosis differ, suggesting that these agents vary in ability to reduce the risk of non-vertebral fractures (NVFs). However, variability among clinical trials in inclusion criteria, baseline characteristics, and definition of NVFs may account for many of these apparent differences.
Data from pivotal trials of individual pharmacologic agents for osteoporosis differ, and suggest that differences may exist between anti-resorptive agents in their ability to reduce the risk of NVFs. Careful examination of these trials’ inclusion criteria and patient characteristics indicates substantial differences between patient populations with respect to the baseline risk of NVFs. When baseline fracture risk is lower, the ability to produce a statistically significant reduction in fracture risk over the course of a clinical trial is reduced.
Analysis of clinical trials reveals that the number and type of baseline vertebral fractures and also baseline bone mineral density, all associated with the risk of vertebral fracture, vary.
Discussion and conclusion
The propensity to fall and patient frailty are additional factors associated with fracture risk that may influence study outcomes. One of the most significant variables, which also often differs considerably between trials, is the definition of an NVF. Variability between clinical trials in inclusion criteria, patients’ baseline characteristics, and how NVFs are defined may account for much of the apparent difference between agents in their ability to reduce NVF risk.
KeywordsAlendronate Bisphosphonate Ibandronate Non-vertebral fractures Risedronate
- 3.Division of Metabolic and Endocrine Drug Products (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Available at: http://www.fda.gov/cder/guidance/osteo.pdf. Accessed January 24, 2008
- 7.National Osteoporosis Foundation. Fast Facts (2008) NOF Web site. Available at: www.nof.org/osteoporosis/diseasefacts.htm. Accessed August 8, 2008
- 8.Eastell R, Reid DM, Compston J et al (2001) Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? Q J Med 94:575–597Google Scholar
- 10.U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Executive Summary (2004) USHHS Web site. Available at: http://www.surgeongeneral.gov/library/bonehealth. Accessed January 26, 2008
- 13.Bonnick S, Hochberg M, Broy S, et al (2005) Comparison of once-weekly alendronate and once-weekly risedronate in the osteoporotic subgroup from the FACT study. Presented at The Sixth International Symposium on Osteoporosis: Current Status and Future Directions: April 6–10; Washington, DCGoogle Scholar
- 17.Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352PubMedCrossRefGoogle Scholar
- 29.Boniva Tablets [package insert] (2006) Roche Pharmaceuticals, Nutley, NJGoogle Scholar
- 33.World Health Organization. WHO scientific group on the assessment of osteoporosis at primary health care level. Summary meeting report. Brussels, Belgium, May 5–7, 2004. Available at: www.who.int/entity/chp/topics/Osteoporosis.pdf. Accessed January 28, 2008
- 37.Pols HA, Felsenberg D, Hanley DA et al (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 9:461–468PubMedCrossRefGoogle Scholar
- 38.Black D, Palermo L, Pols H (2002) Reductions in non-vertebral fracture with alendronate depend on baseline BMD: The FOSIT Study. Osteoporos Int 13(Suppl 1):S22, Abstract P60SUGoogle Scholar
- 44.Bonnick SL (2004) Bone densitometry in clinical practice: application and interpretation, 2nd edn. Humana Press, Totowa, NJ, p 282Google Scholar